Dark Horse Consulting Group's Board of Directors

Anthony Davies, Ph.D.


Anthony Davies, Ph.D. founded Dark Horse Consulting (DHC) in 2014 as the first—and to date, only—consulting practice exclusively focused on Cell and Gene Therapy. Since that time, a global team assembled under his leadership has provided services to numerous clients worldwide. Anthony is known for his considered and sometimes provocative thought-leadership in the space. Before founding Dark Horse, Dr. Davies served as a senior executive for multiple publicly traded and privately held companies, building a reputation of innovation, dedication, and competency.  

Katy Spink, Ph.D.


Katharine (Katy) Spink Ph.D. combines nearly two decades of C&GT operating experience with strategic vision and a well-deserved reputation as an incisive analytical mind. Cross-functional leadership experience across the technical foundations of C&GT makes Katy effective in providing expert guidance in integration and overlap of all industry needs. Dr. Spink’s pre-Dark Horse experience included management consulting with McKinsey & Company as well as executive roles in the field of Cell & Gene Therapy.   

Jeff Clark


Jeff Clark is a Principal at WestView Capital Partners, a Boston-based growth equity firm that made a strategic investment into Dark Horse in 2022. He joined WestView in 2011 and focuses on investments in life sciences and business service companies. Jeff received his B.B.A. in Finance and Accounting from the College of William & Mary and his MBA from the Tuck School of Business at Dartmouth. He began his career in investment banking at BB&T Capital Markets.

David Greenwood, MBA


David Greenwood currently serves as either Board Director or Advisor to several private companies. Between 1995 and December of 2011, Mr. Greenwood served as Chief Financial Officer and Chief Executive Officer of Geron Corporation, a biotechnology company in the fields of regenerative medicine and cancer. From 1979 to 1995, he held a series of senior positions with JPMorgan, an international banking firm. Mr. Greenwood, who holds an MBA from Harvard Business School, is known for his thought-leadership on biotech financing. 

Ronald Park, M.D., MBA


Ronald Park is a physician with extensive experience in multiple biopharma functions, including drug pricing and reimbursement. A McKinsey & Company alumnus and Stanford MD/MBA, Dr. Park spent sixteen years in various leadership roles at Roche and Genentech, before joining Ancestry as EVP of Health and DNA in 2020. In 2021, Ron became CEO of Ambys Medicines. While at Roche/Genentech, Ron co-founded and co-led Roche Personalized Healthcare Center of Excellence, leading the company’s efforts to globally accelerate the use of genomics, real-world data, and digital health for the development and delivery of medicines to patients with serious diseases.

Greg Thomas


Greg Thomas is a General Partner at WestView Capital Partners, a Boston-based growth equity firm that made a strategic investment into Dark Horse in 2022. He joined WestView in 2012 and leads investments in life sciences and technology companies. Prior to WestView, Greg worked at DW Healthcare Partners and Berkshire Partners, with a focus on investments in the healthcare and business services. Greg began his career at Bain & Company.

We use cookies to help give you the best experience on our website. By continuing you agree to our use of cookies.